Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05727384 · ClinicalTrials.gov registry record · Phase 2
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study
A Phase 2 study of Inflammation and Frailty, sponsored by Anne B. Newman.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT05727384: Active Phase 2 study of Inflammation and Frailty, sponsored by Anne B. Newman.
NCT05727384 is a Phase 2 study of Inflammation and Frailty that is active but no longer recruiting, run by Anne B. Newman. The registered enrollment target is 29 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05727384, a Phase 2 study of Inflammation and Frailty, is active but no longer recruiting, sponsored by Anne B. Newman.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the effects of inflammation-lowering therapy on mobility and disability in older adults. The main questions it aims to answer are: * Will therapy improve walking speed/pace? * Will therapy improve levels of blood inflammation markers and other indicators of physical, cognitive and immune function? Participants will be asked to receive injections of drug or placebo every 4 weeks for 24 weeks. They will also be asked to undergo testing that assesses physical function, thinking ability and brain health, breathing capacity, and blood vessel stiffness, and will have blood samples collected to measure immune function and to create a bank of samples for future testing. Comparisons will be made between those who receive drug and those who receive placebo.
Primary Outcome
Assess effect of Clazakizumab versus placebo on speed of walking 400 meters (meters/second) from baseline to 24 weeks
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Clazakizumab
Study Locations (1)
Pennsylvania
- University of Pittsburgh, Health Studies Research Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What the registry record for NCT05727384 still lists
NCT05727384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05727384 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05727384 about?
NCT05727384 is a clinical study titled "Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study". The goal of this clinical trial is to learn about the effects of inflammation-lowering therapy on mobility and disability in older adults. The main questions it aims to answer are: * Will therapy improve walking speed/pace? * Will therapy improve levels of blood inflammation markers and other indic...
What is the current status of trial NCT05727384?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2023-08-01. Estimated completion is 2026-07.
What conditions does trial NCT05727384 study?
This clinical trial studies the following conditions: Inflammation, Frailty.
What interventions are being tested in trial NCT05727384?
The interventions under investigation include: Placebo (DRUG), Clazakizumab (DRUG).
Who is sponsoring clinical trial NCT05727384?
This trial is sponsored by Anne B. Newman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05727384 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05727384's enrollment target sits among peer trials
29 107th of 132 higher than 26 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI